Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
News & Analysis: Nektar Therapeutics
An analyst downgrade is only adding to the company's woes.
Manufacturing issues plague the start-up.
The biotech continues to feel the repercussions from news announced last week.
Find out why these stocks stood out on a down day for the markets.
The biotech's manufacturing problems with a key experimental drug and uncertainty about a major partnership are rattling investors.
The biotech's Q2 numbers weren't nearly as sweet as they were a year ago. But the main focus continues to be on its pipeline progress.
NKTR earnings call for the period ending June 30, 2019.
The company can't seem to sustain any momentum.
A drug candidate was oh-so-close to a regulatory decision, but next month's meeting has been delayed indefinitely.